Key facts
- This page summarizes Aaron VanDevender's Form 4 filing for Applied Molecular Transport Inc..
- 4 reported transactions and 3 derivative rows are listed below.
- Accepted by SEC: 28 Dec 2023, 17:39.
Aaron VanDevender - 27 Dec 2023 Form 4 Insider Report for Applied Molecular Transport Inc.
- Reporting relationship
- Director
- Issuer ticker
- N/A
- Reported as of
- 27 Dec 2023
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 28 Dec 2023, 17:39:57 UTC
- Prior SEC filing
- 15 Jun 2023
- Next SEC filing
- 26 Jun 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Brandon Hants Attorney-in-Fact for Aaron VanDevender
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Aaron VanDevender filed Form 4 for Applied Molecular Transport Inc. on 28 Dec 2023.
Change
- Previous filing in this sequence was filed on 15 Jun 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
AMTI
transaction
Common Stock
Disposed to Issuer
- Transaction value
- Shares
- -212,659
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 27 Dec 2023
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
AMTI
transaction
Derivative
Stock Option (Right to Buy)
Disposed to Issuer
- Transaction value
- $0
- Shares
- -15,395
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 27 Dec 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 15,395
- Exercise price
- $47.01
- Footnotes
- F2
AMTI
transaction
Derivative
Stock Option (Right to Buy)
Disposed to Issuer
- Transaction value
- $0
- Shares
- -20,000
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 27 Dec 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 20,000
- Exercise price
- $3.13
- Footnotes
- F2
AMTI
transaction
Derivative
Stock Option (Right to Buy)
Disposed to Issuer
- Transaction value
- $0
- Shares
- -20,000
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 27 Dec 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 20,000
- Exercise price
- $0.3400
- Footnotes
- F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Section 16 status
Aaron VanDevender is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Explanation of responses 3 footnotes
Footnote F1
Pursuant to the Agreement and Plan of Merger dated as of September 21,2023 (the "Merger Agreement") by and among Cyclo Therapeutics, Inc. ("Cyclo"), Cameo Merger Sub, Inc. and the Issuer, each share of common stock was tendered in exchange for 0.1331 of a share of Cyclo common stock (the "Transaction Consideration"). Upon consummation of the tender offer, the Reporting Person received Transaction Consideration of 28,305 shares of Cyclo common stock.
Footnote F2
Pursuant to the the Merger Agreement, at the effective time of the merger, each outstanding option with an exercise price of $0.40 or more was cancelled effective as of the closing.
Footnote F3
Pursuant to the Merger Agreement, this option was exchanged for an option covering 2,662 shares of Cyclo Common Stock.